FDA-approved for the SFA and full popliteal artery
200 mm stent length that potentially enables a single-stent solution.
Sustained effectiveness up to three years in longer lesions.
Enhanced delivery system is designed to reduce delivery system-dependent stent compression or elongation and enhance deployment accuracy.
FDA-approved stent for the SFA and popliteal artery.
Available in 6 mm and 7 mm diameters and 200 mm in length.
The LifeStent™ Solo™ Vascular Stent System is indicated for the treatment of atherosclerotic lesions in the superficial femoral artery (SFA) and popliteal artery.
1. LifeStent™ Solo™ Vascular Stent Delivery System Study. A single-arm, prospective, non-randomized, multi-center study evaluating the safety and effectiveness of the LifeStent™ Solo™ in the treatment of symptomatic vascular disease of the SFA and/or proximal popliteal artery. Subjects were treated with conventional PTA followed by implantation of the LifeStent™ Vascular Stent. The LifeStent™ 5 mm diameter was not included in this trial.
2. RESILIENT I Trial, RESILIENT II Trial, E-TAGIUSS Trial, Retrospective Analysis of LifeStent® Vascular Stent Systems in the Treatment of Long-Segment Lesions, LifeStent® Vascular Stent Delivery System Study (LifeStent® 200 mm Trial),REALITY I Trial,REALITY II Trial, ETAP Trial, CONTINUUM Trial, and RELIABLE Trial. Additional trials ongoing.
Please consult Instructions for Use for product indications for use, contraindications, warnings, precautions, complications, adverse events and detailed safety information.
BD-23531
1. LifeStent™ Solo™ Vascular Stent Delivery System Study. A single-arm, prospective, non-randomized, multi-center study evaluating the safety and effectiveness of the LifeStent™ Solo™ in the treatment of symptomatic vascular disease of the SFA and/or proximal popliteal artery. Subjects were treated with conventional PTA followed by implantation of the LifeStent™ Vascular Stent. The LifeStent™ 5 mm diameter was not included in this trial.
2. RESILIENT I Trial, RESILIENT II Trial, E-TAGIUSS Trial, Retrospective Analysis of LifeStent® Vascular Stent Systems in the Treatment of Long-Segment Lesions, LifeStent® Vascular Stent Delivery System Study (LifeStent® 200 mm Trial),REALITY I Trial,REALITY II Trial, ETAP Trial, CONTINUUM Trial, and RELIABLE Trial. Additional trials ongoing.
Please consult Instructions for Use for product indications for use, contraindications, warnings, precautions, complications, adverse events and detailed safety information.
